U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491289) titled 'GS1-144 in Participants With Hepatic Impairment and Healthy Female' on March 18.
Brief Summary: GS1-144 in Participants with Hepatic Impairment and Healthy Female
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment and Healthy Female
Intervention:
DRUG: GS1-144 tablet
Administered a single oral dose with GS1-144 tablet 30mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....